Retinal Drugs Sales

Retinal Drugs Sales Market Outlook

The global retinal drugs market is expected to reach approximately USD 10 billion by 2035, growing at a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2025 to 2035. This growth can be attributed to an increasing prevalence of retinal diseases such as age-related macular degeneration and diabetic retinopathy, coupled with advancements in drug formulations and delivery mechanisms. Additionally, an aging population that is more susceptible to eye disorders is driving demand for retinal therapeutics. The rise in awareness regarding early diagnosis and treatment of retinal diseases further propels market growth, alongside significant investments in research and development by pharmaceutical companies striving to introduce innovative treatment options.

Growth Factor of the Market

One of the primary growth factors for the retinal drugs market is the increasing incidence of age-related eye diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy, that are becoming more common due to the rise in diabetes and lifespan. Advances in medical technology and the introduction of novel therapies, such as anti-VEGF agents, have significantly improved treatment outcomes, encouraging more patients to seek treatment. Furthermore, the growing preference for minimally invasive surgeries has led to a surge in demand for retinal drugs that can be administered through intravitreal injections. Another important factor is the rising awareness among healthcare professionals and patients about the importance of early intervention to prevent vision loss, which has also contributed to market expansion. Additionally, the increasing accessibility of healthcare facilities and telemedicine services has facilitated timely diagnosis and treatment, further invigorating market growth. The investment in clinical trials and the development of more effective formulations are also expected to foster the market’s overall trajectory.

Key Highlights of the Market

• The global retinal drugs market is projected to reach USD 10 billion by 2035, with a CAGR of 7.5%.
• A rising geriatric population is significantly influencing the demand for retinal drugs.
• Anti-VEGF drugs are leading the market segment due to their effectiveness in treating various retinal disorders.
• Online pharmacies are gaining traction as a significant distribution channel for retinal drugs.
• North America holds the largest market share, driven by advanced healthcare infrastructure and research initiatives.

By Product Type

Anti-VEGF Drugs:

Anti-VEGF drugs have emerged as the cornerstone of treatment for retinal diseases, primarily due to their efficacy in managing conditions such as age-related macular degeneration and diabetic retinopathy. These medications work by inhibiting vascular endothelial growth factor, thus preventing abnormal blood vessel growth in the retina. With well-established products like Ranibizumab and Aflibercept dominating the market, this segment is expected to witness significant growth driven by strong clinical outcomes and increasing prescriptions from ophthalmologists. The continuous research and development efforts aiming to enhance the efficacy and reduce the side effects of these drugs further solidify their leading position in the retinal drugs market.

Corticosteroids:

Corticosteroids are another vital segment in the retinal drugs market, primarily utilized to reduce inflammation and control symptoms associated with various retinal disorders. Medications such as Dexamethasone and Triamcinolone are commonly administered intravitreally to treat conditions like uveitis and macular edema. This segment is witnessing growth as more clinicians recognize the importance of corticosteroids in managing inflammatory retinal diseases, particularly in patients who do not respond to anti-VEGF therapies. Moreover, advancements in corticosteroid formulations, including sustained-release delivery systems, are expected to enhance patient compliance and treatment outcomes, thus contributing to the segment's expansion.

Immunomodulators:

Immunomodulators play a crucial role in the treatment of autoimmune-related retinal diseases, such as uveitis. These agents help regulate the immune response, thereby alleviating inflammation and preventing damage to retinal tissue. As awareness regarding the impact of immune-mediated conditions on vision increases, the demand for immunomodulators is also expected to rise. The development of novel agents and combination therapies that enhance efficacy while minimizing side effects is likely to encourage greater adoption of immunomodulators in clinical practice, thereby bolstering this segment's growth in the retinal drugs market.

Anti-Infective Drugs:

Anti-infective drugs are essential for treating infections that affect the retina, such as endophthalmitis. The rising incidence of infections, particularly in immunocompromised patients and those undergoing surgical procedures, has underscored the importance of this segment. Moreover, advancements in drug formulations that allow for better penetration into ocular tissues are enhancing the effectiveness of anti-infective therapies. The ongoing development of broad-spectrum antibiotics and antiviral agents tailored for ocular use signifies the potential for growth in this segment, as healthcare providers increasingly prioritize infection prevention and management in retinal care.

Others:

The "Others" category encompasses a range of emerging therapies and drugs that do not strictly fall under the previously mentioned classifications. This may include novel gene therapies and personalized medicine approaches that aim to address specific retinal diseases. As research in the field of retinal therapeutics continues to evolve, the "Others" segment is likely to gain prominence. Investment in innovative treatment modalities aimed at tackling unmet medical needs is expected to drive growth in this segment, attracting interest from pharmaceutical companies and researchers alike.

By Application

Age-related Macular Degeneration:

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among the elderly, making it a significant focus within the retinal drugs market. The growing geriatric population, coupled with increased awareness of AMD, is propelling the demand for effective treatments. Anti-VEGF therapies, in particular, have demonstrated significant success in managing wet AMD, leading to improved patient outcomes. With ongoing research aimed at developing longer-lasting therapies and alternative treatment options, this application segment is expected to witness substantial growth as more individuals seek timely intervention for AMD.

Diabetic Retinopathy:

Diabetic retinopathy is a condition that affects a substantial proportion of individuals with diabetes, resulting in vision impairment and potential blindness. The increasing prevalence of diabetes globally is a critical driver for the retinal drugs market, particularly in the diabetic retinopathy segment. Anti-VEGF and corticosteroid therapies are commonly used to manage this condition, and ongoing advancements in treatment protocols are improving patient management. As healthcare initiatives focus on diabetes prevention and control, the demand for effective retinal therapies for diabetic retinopathy is likely to rise, further stimulating market growth.

Retinal Vein Occlusion:

Retinal vein occlusion represents another significant application segment within the retinal drugs market. This condition can cause sudden vision loss and is often associated with other underlying health issues, such as hypertension and diabetes. The use of anti-VEGF treatments and corticosteroids has become standard practice in managing retinal vein occlusion, allowing patients to preserve their vision. The segment's growth will be driven by increasing diagnosis rates and improvements in treatment strategies, with a particular emphasis on early detection and intervention to minimize long-term effects.

Uveitis:

Uveitis, an inflammation of the uveal tract, can lead to serious complications, including vision loss if not treated appropriately. The retinal drugs market is experiencing growth in the uveitis segment as awareness of the disease and its impact on vision increases. Immunomodulatory therapies and corticosteroids are the primary treatment options, with ongoing research aimed at developing more effective and targeted therapies for this condition. As uveitis is often underdiagnosed, increased screening efforts and educational campaigns by healthcare organizations are expected to foster greater demand for retinal drugs in this application area.

Others:

The "Others" application category includes various less common retinal disorders that require pharmacological intervention. These may consist of conditions such as choroidal neovascularization or inherited retinal dystrophies. As advancements in genetics and molecular biology continue to unravel the complexities of these diseases, tailored therapies may emerge, driving growth in this application segment. Increased investment in research and development for rare retinal diseases signifies an expanding market potential, as pharmaceutical companies pivot towards addressing specific and unique therapeutic needs.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of retinal drugs, particularly as they serve as centers for complex patient care. Hospitals often provide comprehensive management for retinal diseases, enabling easy access to specialized medications. The presence of ophthalmology departments within hospitals ensures that patients receive timely treatment and follow-up care. As the demand for specialized care increases, hospital pharmacies are expected to maintain significant market share, driven by strong relationships with healthcare providers and a focus on patient-centered treatment approaches.

Retail Pharmacies:

Retail pharmacies are an important distribution channel for retinal drugs, providing accessibility to patients who may prefer to obtain their medications locally. The growing trend of chronic disease management has heightened the demand for retinal drugs through retail outlets. Competitive pricing and promotional offers by retail pharmacies can enhance patient adherence to prescribed therapies. As a result, retail pharmacies are positioned to capture a substantial share of the market, particularly in regions with a well-developed pharmacy network that emphasizes patient education and support.

Online Pharmacies:

Online pharmacies have revolutionized the way patients access retinal medications, particularly as the convenience of e-commerce continues to gain popularity. Patients can order medications from the comfort of their homes, which is especially beneficial for those with mobility issues or residing in remote areas. The rise of telemedicine and digital health platforms has further propelled the growth of online pharmacies, enhancing patient engagement in their treatment processes. As the online pharmacy market expands, it is expected to play a significant role in the distribution of retinal drugs, providing competitive pricing and prompt delivery services.

By Ingredient Type

Ranibizumab:

Ranibizumab is one of the leading ingredients used in the treatment of retinal diseases, particularly wet age-related macular degeneration and diabetic retinopathy. Its efficacy in inhibiting vascular endothelial growth factor (VEGF) has established it as a first-line treatment option. The wide acceptance of Ranibizumab among clinicians, along with its proven clinical outcomes, has solidified its dominance in the retinal drugs market. Ongoing research aimed at exploring new applications and formulations of Ranibizumab continues to enhance its relevance within the market.

Aflibercept:

Aflibercept is another prominent ingredient in the retinal drugs market, recognized for its dual mechanism of action in both inhibiting VEGF and placental growth factor. Its effectiveness in treating conditions like wet AMD and retinal vein occlusion has propelled its adoption among ophthalmologists. The convenience of extended dosing intervals compared to other anti-VEGF agents adds to its appeal, ensuring more manageable treatment regimens for patients. Aflibercept's continuous presence in clinical studies is likely to foster further innovations and enhance its market share.

Triamcinolone:

Triamcinolone is a corticosteroid frequently employed in retinal treatments, particularly for inflammation associated with uveitis and diabetic macular edema. Its anti-inflammatory properties have established it as a valuable addition to the retinal drugs arsenal, often used in conjunction with other therapies. The development of new injectable formulations of Triamcinolone is anticipated to boost its utilization and effectiveness, particularly in intraocular applications. As the demand for anti-inflammatory therapies increases, Triamcinolone is likely to maintain its significance in the retinal drugs market.

Dexamethasone:

Dexamethasone, another corticosteroid, is utilized in the management of various ocular inflammatory diseases and complications post-surgery. Its use in sustained-release formulations, such as the Dexamethasone implant, has enhanced its effectiveness and patient compliance. The ability to provide localized therapy with reduced systemic exposure increases its appeal among healthcare providers. As the focus on personalized treatment plans grows, Dexamethasone is expected to remain a cornerstone in retinal therapeutics, particularly for conditions requiring long-term management.

Ganciclovir:

Ganciclovir is an antiviral medication used primarily for treating viral infections of the retina, such as cytomegalovirus (CMV) retinitis. It plays a crucial role in managing ocular infections, particularly in immunocompromised patients. The increasing incidence of viral infections in patients with conditions like HIV/AIDS necessitates the availability of effective antiviral treatments. As research continues to explore the potential of Ganciclovir in combination therapies and novel delivery systems, its importance in the retinal drugs market is expected to grow, addressing urgent therapeutic needs.

By Region

North America dominates the retinal drugs market, accounting for nearly 40% of the global share, driven by the high incidence of retinal disorders and advanced healthcare infrastructure. The increasing investments in ophthalmic research and development, coupled with a well-established presence of key pharmaceutical companies, further strengthens the region's position. The CAGR for the North American retinal drugs market is projected to be around 7.8%, supported by benefits such as early diagnosis, increased health insurance coverage, and a growing emphasis on specialty care. The rising awareness about retinal diseases and the importance of timely treatment is expected to maintain this growth trajectory throughout the forecast period.

Europe follows North America closely, holding a substantial share of the retinal drugs market, estimated at around 30%. The region benefits from a highly developed healthcare system, along with increasing initiatives to improve awareness and access to retinal treatments. Countries like Germany, France, and the UK are leading contributors to market growth, attributed to their robust research and development landscape and government support for innovative health solutions. The CAGR for the European market is estimated at 6.5%, reflecting the ongoing trends toward improved patient management and the need for effective treatments for prevalent retinal diseases. Furthermore, the implementation of stringent regulatory policies ensures high standards of product safety and efficacy, further enhancing market growth.

Opportunities

The retinal drugs market is poised for substantial growth, particularly driven by emerging opportunities in drug development and personalized medicine. With the increasing prevalence of retinal disorders worldwide, there is an urgent need for innovative therapies that address specific patient needs. Pharmaceutical companies are actively investing in research and development to create next-generation retinal drugs that offer improved efficacy, safety, and convenience. The potential for breakthrough therapies, such as gene therapy and regenerative medicine, represents a new frontier in the treatment of retinal diseases, offering hope for conditions that currently have limited treatment options. Additionally, the integration of digital health technologies, such as telehealth consultations and remote monitoring, presents opportunities to enhance patient engagement and improve treatment adherence, ultimately contributing to better health outcomes.

Furthermore, the growing trend of collaborations between pharmaceutical companies and biotechnology firms is expected to spur innovation in the retinal drugs market. By combining expertise and resources, these partnerships can streamline the development of novel therapies and facilitate quicker market entry. The expansion of healthcare access in emerging economies is another significant opportunity, as increased investment in healthcare infrastructure and rising patient awareness pave the way for market growth in these regions. As the focus on preventive care continues to grow, there is an opportunity for retinal drugs to play a critical role in early diagnosis and treatment, thereby reducing the overall burden of vision-related issues and promoting better quality of life.

Threats

Despite the promising outlook for the retinal drugs market, several threats could hinder its growth trajectory. One significant challenge is the rising cost of healthcare, which can limit patient access to necessary treatments, especially in resource-limited settings. This economic strain can impact the uptake of retinal drugs, ultimately leading to poorer health outcomes. Additionally, the prevalence of counterfeit drugs poses a substantial risk in the pharmaceutical industry, including retinal therapies. The circulation of substandard medications can undermine treatment efficacy, erode patient trust, and lead to serious health complications, necessitating stringent regulatory measures to combat this issue.

Moreover, the rapid pace of technological advancements in the field of medicine raises the threat of obsolescence for existing retinal drugs. As new therapies emerge, particularly those demonstrating superior efficacy or lower side effects, older drugs may lose market relevance. Consequently, pharmaceutical companies must remain agile and invest in continuous research and development to stay competitive. Intellectual property challenges and patent expirations can also pose threats as generic alternatives become available, potentially leading to price erosion and market share loss for original manufacturers. Finally, the overall economic environment and changes in healthcare policies, particularly in reimbursement frameworks, can impact the financial viability of retinal drug products, making it essential for companies to adapt to these evolving landscapes.

Competitor Outlook

• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Bausch Health Companies Inc.
• Genentech, Inc. (Roche)
• Alcon Inc.
• Valeant Pharmaceuticals International, Inc.
• Ocular Therapeutix, Inc.
• Amgen Inc.
• Horizon Therapeutics PLC
• AbbVie Inc.
• Eyepoint Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Merck & Co., Inc.

The competitive landscape of the retinal drugs market is characterized by a mix of established pharmaceutical giants and emerging biotech companies, each striving to innovate and capture market share. Key players such as Novartis and Regeneron dominate the field with their core offerings of anti-VEGF therapies, which continue to be the mainstay for treating various retinal conditions. The emphasis on research and development has propelled these companies to the forefront, allowing them to expand their product lines and enhance treatment options. The increasing competition has also fostered a climate of collaboration, with companies teaming up to leverage their respective strengths in drug development, clinical trials, and market reach.

Regeneron Pharmaceuticals, along with Novartis, remains a strong contender with its flagship product Eylea, which is widely used for the treatment of multiple retinal disorders. The ongoing clinical research and trials aim to explore the efficacy of Eylea in new indications, which will likely reinforce its market position. Novartis, with its comprehensive portfolio of retinal drugs, is also investing heavily in emerging therapies and delivery systems, demonstrating a commitment to meeting patient needs and maintaining its competitive edge in the market. Both companies exemplify the importance of innovation within the sector, as they continuously seek to improve patient outcomes through advanced therapeutics.

Emerging players, such as Ocular Therapeutix and Eyepoint Pharmaceuticals, are also making significant strides in the retinal drugs market by focusing on novel delivery systems and formulations. These companies are dedicated to addressing unmet needs and enhancing patient compliance through technologies like sustained-release implants and innovative drug formulations. As the landscape evolves, the strategic focus on patient-centered care and personalized medicine is expected to foster further competition and innovation, resulting in improved therapeutic options for retinal disease patients. The landscape reflects the dynamic nature of the industry, as companies adapt to new challenges and opportunities while striving to deliver superior products and services to healthcare providers and patients alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Alcon Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Novartis AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Pfizer Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Merck & Co., Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 F. Hoffmann-La Roche AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Genentech, Inc. (Roche)
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Horizon Therapeutics PLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Ocular Therapeutix, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bausch Health Companies Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eyepoint Pharmaceuticals, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Santen Pharmaceutical Co., Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Valeant Pharmaceuticals International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Retinal Drugs Sales Market, By Application
    • 6.1.1 Age-related Macular Degeneration
    • 6.1.2 Diabetic Retinopathy
    • 6.1.3 Retinal Vein Occlusion
    • 6.1.4 Uveitis
    • 6.1.5 Others
  • 6.2 Retinal Drugs Sales Market, By Product Type
    • 6.2.1 Anti-VEGF Drugs
    • 6.2.2 Corticosteroids
    • 6.2.3 Immunomodulators
    • 6.2.4 Anti-Infective Drugs
    • 6.2.5 Others
  • 6.3 Retinal Drugs Sales Market, By Ingredient Type
    • 6.3.1 Ranibizumab
    • 6.3.2 Aflibercept
    • 6.3.3 Triamcinolone
    • 6.3.4 Dexamethasone
    • 6.3.5 Ganciclovir
  • 6.4 Retinal Drugs Sales Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Retinal Drugs Sales Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Retinal Drugs Sales market is categorized based on

By Product Type

• Anti-VEGF Drugs
• Corticosteroids
• Immunomodulators
• Anti-Infective Drugs
• Others

By Application

• Age-related Macular Degeneration
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Uveitis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Ranibizumab
• Aflibercept
• Triamcinolone
• Dexamethasone
• Ganciclovir

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Regeneron Pharmaceuticals, Inc.
• Bausch Health Companies Inc.
• Genentech, Inc. (Roche)
• Alcon Inc.
• Valeant Pharmaceuticals International, Inc.
• Ocular Therapeutix, Inc.
• Amgen Inc.
• Horizon Therapeutics PLC
• AbbVie Inc.
• Eyepoint Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• F. Hoffmann-La Roche AG
• Pfizer Inc.
• Merck & Co., Inc.